New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo™ (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers

- Data demonstrated durable objective responses across both the RET fusion-positive NSCLC and RET-altered thyroid cancer patient cohorts INDIANAPOLIS , Aug. 27, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine ( NEJM ) published Phase